HIV-1 kan være assosiert med økte lipidnivåer, noe som kan føre til dyslipidemi
Behandling med ARV kan også ha effekt på lipider
aStatistiske analyser var ikke predefinert for disse kategoriene.
Adaptert fra Molina JM, Squires K, Sax P E et al., 20181
aStatistiske analyser var ikke predefinert for disse kategoriene.
Adaptert fra Orkin C, Squires K E, Molina JM, et al.,20182
Orkin C, Squires K E, Molina JM, et al. Doravirine/Lamivudine/Tenofovir Disoproxil Fumarate is Non-inferior to Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate in Treatment-naïve Adults With Human Immunodeficiency Virus-1 Infection: week 48 Results of the DRIVE-AHEAD Trial. Clin Infect Dis. 2018. Epub 2018 August 31
Molina JM, Squires K, Sax P E et al. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naïve adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomized, double-blind, phase 3, non-inferiority trial. Lancet HIV. 2018;5(5):e211-e220. doi:10.1016/S2352-3018(18)30021-3. Epub 2018 March 25.
Hussain NE, Ahmed M, Managing dyslipedimia in HIV/AIDS patients: chalenges and solutions, HIV/AIDS - Research and Pallative care, 2015:7 1-10
Atkinson EC, Hadigan C, Management of dyslipedima in HIV infection, Clinical Lipidology, 7:6, 603-606
Viskovic K, Lepej SZ, Gorenec A, et al, Cardiovascular markers of inflammation and serum lipid levels in HIV-infected patients with undetectable viremia, Scientific Reports 2018, 8:6113